BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

Jacobio Gains China CDE Approval for Phase III SHP2 and KRAS G12C Inhibitor Trial

This approved study in China is a randomized active controlled phase III trial design to evaluate the efficacy and safety of JAB-3312 in combinat...

February 19, 2024 | News

FDA Prioritizes Review of Bristol Myers Squibb's Augtyro™ for NTRK-Positive Solid Tumors

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for A...

February 15, 2024 | News

BioAge Secures $170 Million in Series D Funding to Propel Obesity and Metabolic Disease Drug Development

BioAge Labs (“BioAge”), a pioneering biotechnology firm dedicated to advancing novel treatments for obesity and metabolic diseases by e...

February 14, 2024 | News

Brii Biosciences Secures Intellectual Property Rights for HBV Treatment from VBI Vaccines

Brii Biosciences Limited ("Brii Bio"), a leader in developing innovative treatments for diseases with significant unmet needs, has announced a strategic ac...

February 14, 2024 | News

Otsuka's AVP-786 Falls Short in Phase 3 Trial for Alzheimer's Agitation

Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) and its parent company Otsuka Pharmaceutical, Co. Ltd. (Otsuka) have released the t...

February 13, 2024 | News

Gilead Sciences Bolsters Liver Portfolio Through Acquisition of CymaBay Therapeutics

Gilead Sciences, Inc. and CymaBay Therapeutics, Inc. announced today a definitive agreement whereby Gilead will acquire CymaBay for $32.50 ...

February 13, 2024 | News

CSL Reveals Phase 3 AEGIS-II Trial Results for CSL112

"We look forward to sharing our scientific learnings regarding cholesterol efflux and recurrent cardiovascular events," said C. Michael Gibson, M.S., ...

February 12, 2024 | News

Zymedi initiates first human dosing of ZMA001 in a clinical trial for Pulmonary Arterial Hypertension in South Korea

In collaboration with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH), Zymedi is conducting this t...

February 09, 2024 | News

SMC Laboratories Unveils STAM™-HCC/IO+ Mouse for Advancing Liver Cancer Drug Development in Immuno-Oncology

The company specializes in liver-related services and has evaluated test substances in over 15 MOA categories as well as over 270 target molecules us...

February 07, 2024 | News

ShiraTronics finishes Australian pilot study enrollment, gears up for pivotal clinical trial

Migraine, recognized globally as a significant cause of disability, particularly among pre-menopausal women, poses a substantial health challenge. For arou...

February 07, 2024 | News

Stakeholders Rally for Sustainable Funding to Secure Australia's Future of National One Stop Shop for Clinical Trials

The NOSS, a pioneering digital platform, seeks to streamline the approval and reporting procedures for human research, particularly clinical trials, in Aus...

February 06, 2024 | News

Genesis MedTech Finishes U.S. Study Enrollment for J-Valve™ in Severe Aortic Regurgitation

Genesis MedTech, a leading medical device company, today announced the completion of enrollment in its United States Early Feasibility Study (EFS) usi...

February 06, 2024 | News

NouvNeu001 Marks Milestone in iRegene's c Trial with Successful First Patient Dosing

It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, an...

February 06, 2024 | News

Pliant Therapeutics Reports Positive Results in Bexotegrast Trial for Liver Fibrosis

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety conce...

February 05, 2024 | News

Stay Connected